Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease
| Autor: | Herb DeRiesthal, Dale B. Glasser, Michael O. Sweeney, Carl J. Pepine, Arkady Shpilsky, Robert F. DeBusk |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Sildenafil Vasodilator Agents Coronary Disease Placebo Piperazines Sildenafil Citrate law.invention Coronary artery disease chemistry.chemical_compound Patient satisfaction Double-Blind Method Erectile Dysfunction Randomized controlled trial 3' 5'-Cyclic-GMP Phosphodiesterases law Internal medicine Outcome Assessment Health Care medicine Humans Prospective Studies Sulfones Prospective cohort study Adverse effect business.industry Penile Erection Middle Aged medicine.disease respiratory tract diseases Surgery Erectile dysfunction chemistry Patient Satisfaction Purines cardiovascular system Cardiology Safety Cardiology and Cardiovascular Medicine business |
| Zdroj: | The American Journal of Cardiology. 93:147-153 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2003.09.030 |
| Popis: | This was a double-blind, placebo-controlled, flexible-dose study of the efficacy and safety of sildenafil in men with erectile dysfunction (ED) and clinically stable coronary artery disease (CAD). Patients were randomized to receive sildenafil or placebo for 12 weeks. Primary outcomes were questions 3 and 4 of the International Index of Erectile Function (IIEF). Secondary outcomes included the other IIEF questions and functional domains, the Life Satisfaction Checklist, the Erectile Dysfunction Inventory of Treatment Satisfaction, 2 global efficacy assessment questions, and intercourse success rate. By week 12, sildenafil-treated patients (n = 70) showed significant improvements on questions 3 and 4 compared with placebo-treated patients (n = 72; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect